CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

Background and aims: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing-remitting phase of multiple sclerosis (MS). However, its efficacy in progr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeroen FJ Bogie (Author), Elien Grajchen (Author), Elien Wouters (Author), Bieke Broux (Author), Piet Stinissen (Author), Bart Van Wijmeersch (Author), Jerome JA Hendriks (Author)
Format: Book
Published: SAGE Publishing, 2020-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items